MedDay, a biotechnology company focused on the treatment of nervous system disorders, has boosted its research platform by acquiring the health division of Profilomic SA, a company formed out of Commissariat à l’Energie Atomique (CEA) in 2010. The acquisition will allow MedDay to strengthen its existing metabolomics research platform, SPECMET, with the aim of expanding its pipeline of neurological disorder therapies.

MedDay has acquired all of the health-related assets from Profilomic, including an extensive database and laboratory equipment alongside a team of scientists with expertise in the field of metabolomics and lipidomics. SPECMET was developed in collaboration with the CEA and this acquisition will further strengthen the existing partnership and the research platform will remain close to its scientific origins at the CEA. Financial terms are undisclosed.

The MedDay SPECMET platform supports the discovery of additional pipeline assets by identifying new therapeutic targets through metabolomics analysis of cerebrospinal fluid (CSF). SPECMET screens CSF from patients with various central nervous system (CNS) disorders to identify the disrupted metabolic pathways. 

“Tackling unmet medical need in central nervous system disorders by acting on brain metabolism is the driving force behind MedDay,” said Frédéric Sedel, chief executive officer, MedDay. “With the acquisition of Profilomic, we have significantly expanded our research capabilities and are excited to expand our pipeline. MedDay is moving towards its goal of building a fully integrated biotechnology company, operating from discovery through to commercialization.”